Edition:
India

Endo International PLC (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

3.50USD
4 Aug 2020
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.50
Open
--
Day's High
--
Day's Low
--
Volume
2
Avg. Vol
1,426,903
52-wk High
$7.10
52-wk Low
$1.97

Latest Key Developments (Source: Significant Developments)

Endo International Reports Q1 EPS From Cont Ops Of $0.68
Thursday, 7 May 2020 

May 7 (Reuters) - Endo International PLC ::Q1 REVENUE 820 MILLION USD VERSUS 720 MILLION USD YEAR AGO.Q1 DILUTED EPS FROM CONTINUING OPERATIONS 0.68 USD VERSUS 0.06 USD LOSS YEAR AGO.FULL-YEAR 2020 FINANCIAL GUIDANCE WITHDRAWN DUE TO UNCERTAINTY REGARDING CONTINUED IMPACT OF COVID-19 PANDEMIC.SEES SECOND-QUARTER 2020 TOTAL REVENUES TO DECLINE IN LOW 20'S PERCENTAGE RANGE COMPARED TO FIRST-QUARTER OF 2020.TOTAL REVENUES WERE $820 MILLION IN FIRST-QUARTER 2020 COMPARED TO $720 MILLION DURING SAME PERIOD IN 2019.  Full Article

Endo Reports Q1 Adjusted Earnings Per Share $0.95
Thursday, 7 May 2020 

May 7 (Reuters) - Endo International PLC ::ENDO REPORTS FIRST-QUARTER 2020 FINANCIAL RESULTS AND PROVIDES UPDATE RELATING TO COVID-19 PANDEMIC.Q1 ADJUSTED EARNINGS PER SHARE $0.95 FROM CONTINUING OPERATIONS.Q1 EARNINGS PER SHARE $0.68 FROM CONTINUING OPERATIONS.Q1 REVENUE $820 MILLION VERSUS REFINITIV IBES ESTIMATE OF $712.8 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.55 -- REFINITIV IBES DATA.FULL-YEAR 2020 FINANCIAL GUIDANCE WITHDRAWN.ENDO INTERNATIONAL - LAUNCH OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM FOR TREATMENT OF CELLULITE IN BUTTOCKS MOVED TO FIRST-QUARTER 2021.ANTICIPATES MODEST DELAYS IN PATIENT RECRUITMENT AND SITE SELECTION FOR NEW CLINICAL TRIALS AND ONGOING STUDIES.ANTICIPATES A DECLINE IN GENERIC PHARMACEUTICALS REVENUES IN SECOND-QUARTER OF 2020 COMPARED TO FIRST-QUARTER OF 2020.SEES Q2 TOTAL REVENUES TO DECLINE IN LOW 20'S PERCENTAGE RANGE COMPARED TO FIRST-QUARTER OF 2020.SEES Q2 ADJUSTED GROSS MARGIN TO BE APPROXIMATELY 60 PERCENT OF REVENUES.SEES Q2 ADJUSTED OPERATING EXPENSES TO BE APPROXIMATELY 25 PERCENT OF REVENUES.  Full Article

Endo International Says CEO Paul V. Campanelli's FY 2019 Total Compensation Was $13.1 Mln Vs $20 Mln In 2018
Wednesday, 29 Apr 2020 

April 28 (Reuters) - Endo International PLC ::ENDO INTERNATIONAL PLC SAYS CEO PAUL V. CAMPANELLI'S FY 2019 TOTAL COMPENSATION WAS $13.1 MILLION VERSUS $20 MILLION IN 2018 - SEC FILING.ENDO INTERNATIONAL - CEO PAY RATIO OF ANNUAL TOTAL COMPENSATION OF CEO TO ANNUAL TOTAL COMPENSATION OF MEDIAN EMPLOYEE IS ABOUT 148 TO 1 FOR 2019.  Full Article

Endo Expects To Launch Cellulite Treatment In Q4 2020, If Approved
Wednesday, 26 Feb 2020 

Feb 26 (Reuters) - Endo International PLC ::ENDO EXEC SAYS WHILE OPIOID SETTLEMENTS ARE ONGOING, CO IS PREPARED TO LITIGATE, IF NECESSARY - CONF CALL.ENDO EXEC SAYS EXPECT FY'20 STERILE INJECTABLES REVENUES TO GROW IN THE LOW TO MID SINGLE DIGIT PERCENTAGE RANGE- CONF CALL.ENDO EXEC SAYS EXPECT TO LAUNCH CELLULITE TREATMENT IN Q4 2020, IF APPROVED - CONF CALL.  Full Article

Endo Reports Q4 Loss Per Share Of $0.92 From Continuing Operations
Wednesday, 26 Feb 2020 

Feb 26 (Reuters) - Endo International PLC ::ENDO REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS.Q4 ADJUSTED EARNINGS PER SHARE $0.74 FROM CONTINUING OPERATIONS.Q4 LOSS PER SHARE $0.92 FROM CONTINUING OPERATIONS.Q4 REVENUE $765 MILLION VERSUS REFINITIV IBES ESTIMATE OF $731.4 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $0.57 -- REFINITIV IBES DATA.SEES 2020 TOTAL REVENUES TO BE BETWEEN $2.72 BILLION AND $2.92 BILLION.SEES 2020 ADJUSTED DILUTED NET INCOME PER SHARE FROM CONTINUING OPERATIONS TO BE BETWEEN $2.15 AND $2.40.ENDO INTERNATIONAL - 2020 GUIDANCE FOR ADJUSTED EARNINGS PER SHARE FROM CONTINUING OPERATIONS, ADJUSTED EBITDA & ADJUSTED OPERATING EXPENSES EXCLUDE OPIOID-RELATED LEGAL EXPENSES.QTRLY BRANDED PHARMACEUTICALS REVENUES WERE $226 MILLION COMPARED TO $230 MILLION.QTRLY SPECIALTY PRODUCTS REVENUES INCREASED 15% TO $149 MILLION.FY2020 EARNINGS PER SHARE VIEW $2.25, REVENUE VIEW $2.90 BILLION -- REFINITIV IBES DATA.  Full Article

Endo Names Blaise Coleman President And Chief Executive Officer
Thursday, 20 Feb 2020 

Feb 19 (Reuters) - Endo International PLC ::ENDO NAMES BLAISE COLEMAN PRESIDENT AND CHIEF EXECUTIVE OFFICER.ENDO INTERNATIONAL PLC - MARK BRADLEY NAMED EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER.ENDO INTERNATIONAL PLC - COLEMAN WILL SUCCEED PAUL CAMPANELLI AS PRESIDENT AND CHIEF EXECUTIVE OFFICER.ENDO INTERNATIONAL PLC - PAUL CAMPANELLI WILL CONTINUE TO SERVE AS CHAIRMAN OF BOARD.ENDO INTERNATIONAL PLC - SEPARATELY, MARK G. BARBERIO WAS APPOINTED TO BOARD OF DIRECTORS.  Full Article

Endo Announces FDA Acceptance Of Original Biologics License Application For Collagenase Clostridium Histolyticum To Treat Cellulite
Wednesday, 20 Nov 2019 

Nov 19 (Reuters) - Endo International PLC ::ENDO ANNOUNCES FDA'S ACCEPTANCE OF ORIGINAL BIOLOGICS LICENSE APPLICATION (BLA) FOR COLLAGENASE CLOSTRIDIUM HISTOLYTICUM (CCH) IN PATIENTS WITH CELLULITE.ENDO INTERNATIONAL PLC - PRESCRIPTION DRUG USER FEE ACT (PDUFA), OR TARGET ACTION DATE FOR BLA, HAS BEEN SET FOR JULY 6, 2020..ENDO INTERNATIONAL PLC - BLA FOR COLLAGENASE CLOSTRIDIUM HISTOLYTICUM IS SUPPORTED BY RESULTS OF RELEASE-1 AND RELEASE-2 PHASE 3 STUDIES.  Full Article

Endo Says No "Direct News" From FDA About Application For Approval Of Cellulite Treatment
Tuesday, 5 Nov 2019 

Nov 5 (Reuters) - Endo International PLC ::ENDO CEO SAYS "WHILE SETTLEMENT REMAINS OUR GOAL, WE ARE PREPARED TO LITIGATE IF NECESSARY" IN REFERENCE TO OPIOID LAWSUITS - CONF. CALL.ENDO SAYS CONTINUING TO TAKE APPROPRIATE STEPS TO PREPARE FOR REGULATORY APPROVAL OF CELLULITE TREATMENT IN SECOND HALF OF 2020 - CONF. CALL.ENDO SEES HIGH LEVEL OF COMPETITION IN GENERICS BUSINESS DRIVEN BY NEW MARKET ENTRANTS - CONF. CALL.ENDO SEES 2019 BRANDED SPECIALTY PRODUCT PORTFOLIO REVENUE GROWING IN MID TEENS PERCENTAGE VERSUS. PRIOR EXPECTATION OF LOW DOUBLE DIGIT PERCENTAGE - CONF. CALL.ENDO RAISES 2019 XIAFLEX SALES GROWTH FORECAST TO ABOUT 20% VERSUS. PRIOR VIEW OF MID TO HIGH TEENS PERCENTAGE.ENDO SAYS 2019 VASOSTRICT REVENUE EXPECTED TO GROW IN LOW DOUBLE DIGIT PERCENT - CONF. CALL.ENDO CEO SAYS DECISION TO RESIGN WAS A PERSONAL LIFE DECISION, SAYS BELIEVES CO IS IN "BEST POSITION FOR GROWTH" - CONF. CALL.ENDO CEO SAYS "NOTHING STOPPING US" FROM BRINGING IN SMALL DEALS FOR SPECIALTY AND STERILE INJECTABLES BUSINESSES - CONF. CALL.ENDO SAYS NO "DIRECT NEWS" FROM FDA ABOUT CO'S APPLICATION FOR APPROVAL OF TREATMENT FOR CELLULITE - CONF. CALL.  Full Article

Endo Implements Says Chief Executive Officer Paul Campanelli To Retire
Tuesday, 5 Nov 2019 

Nov 4 (Reuters) - Endo International PLC ::ENDO IMPLEMENTS CEO SUCCESSION PLAN.ENDO INTERNATIONAL PLC - PAUL CAMPANELLI APPOINTED CHAIRMAN OF BOARD.ENDO INTERNATIONAL PLC - PAUL CAMPANELLI WILL ALSO CONTINUE AS PRESIDENT AND CHIEF EXECUTIVE OFFICER UNTIL SUCCESSOR APPOINTED.ENDO INTERNATIONAL - PAUL V. CAMPANELLI, PRESIDENT AND CHIEF EXECUTIVE OFFICER HAS NOTIFIED BOARD OF DIRECTORS OF HIS INTENTION TO RETIRE.  Full Article

Endo Implements CEO Succession Plan
Tuesday, 5 Nov 2019 

Nov 4 (Reuters) - Endo International PLC ::ENDO IMPLEMENTS CEO SUCCESSION PLAN.ENDO INTERNATIONAL PLC - ROGER KIMMEL APPOINTED SENIOR INDEPENDENT DIRECTOR.ENDO INTERNATIONAL PLC - PAUL CAMPANELLI APPOINTED CHAIRMAN OF BOARD, WILL ALSO CONTINUE AS PRESIDENT AND CEO UNTIL SUCCESSOR APPOINTED.ENDO INTERNATIONAL PLC - BOARD IS LAUNCHING A PROCESS TO IDENTIFY CAMPANELLI'S SUCCESSOR.  Full Article

BRIEF-U.S. FDA Approves Qwo™ (Collagenase Clostridium Histolyticum-Aaes), The First Injectable Treatment For Cellulite

* U.S. FDA APPROVES QWO™ (COLLAGENASE CLOSTRIDIUM HISTOLYTICUM-AAES), THE FIRST INJECTABLE TREATMENT FOR CELLULITE